Want to join the conversation?
$VRTX reported total CF product revenues of approx. $426MM in 2Q16 versus $155MM in 2Q15. Orkambi drug sales were $245MM. Kalydeco drug sales were up $25MM to $108MM. Operating expenses rose in 2Q16, due to increased costs related to the progression of CF pipeline and increased investments in global commercial support for the launch of Orkambi.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.